A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

​ Conditions: Solid Tumor (Phase I); RAS Mutation; CEACAM5

Interventions: Drug: Intravenous AN4035; Drug: Intravenous AN4035 followed by intravenous EGFR Inhibitor.

Sponsors: Adlai Nortye Biopharma Co., Ltd.

Not yet recruiting Conditions: Solid Tumor (Phase I); RAS Mutation; CEACAM5
Interventions: Drug: Intravenous AN4035; Drug: Intravenous AN4035 followed by intravenous EGFR Inhibitor.
Sponsors: Adlai Nortye Biopharma Co., Ltd.
Not yet recruiting